RUBY
$14.40
Rubius Therapeutics
($.97)
(6.31%)
RUBY
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.56)
Revenue:  $0.00 Mil
Monday
Nov 8
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RUBY reports earnings?
Beat
Meet
Miss

Where is RUBY's stock price going from here?
Up
Flat
Down
Stock chart of RUBY
Analysts
Summary of analysts' recommendations for RUBY
Score
Grade
Pivots
Resistance
$16.45
$16.16
$15.76

$15.47

Support
$15.07
$14.78
$14.38
Tweet
Growth
Description
Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.